Day: June 3, 2024

Getty Realty Corp. Publishes 2024 Corporate Responsibility Report

Written by Customer Service on . Posted in Public Companies.

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) — Getty Realty Corp. (NYSE: GTY) announced today that it has published its 2024 Corporate Responsibility Report highlighting the Company’s environmental, social and governance (“ESG”) policies and practices. Getty engaged Antea® Group, an Environment, Health, Safety, and Sustainability consulting firm, to assist with the report which was prepared with consideration of the frameworks established by the Sustainability Accounting Standards Board (SASB) and the Task Force on Climate-Related Financial Disclosures (TCFD). “Our third annual Corporate Responsibility Report provides insight into our consistent efforts to deepen our relationships with key stakeholders, and reaffirms our ongoing commitment to effective ESG practices,” said Christopher J. Constant, Getty’s President &...

Continue reading

PetMed Express, Inc. Announces Strategic Updates to Executive Leadership Team

Written by Customer Service on . Posted in Public Companies.

Caroline Conegliano Caroline Conegliano Umesh Sripad Umesh Sripad Caroline Conegliano appointed Chief Operating Officer Umesh Sripad appointed Chief Digital and Technology Officer Company Announces CFO transition DELRAY BEACH, Fla., June 03, 2024 (GLOBE NEWSWIRE) — PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”) today announced several changes to its executive leadership team to further advance key initiatives to improve the customer experience, and to accelerate growth and profitability. Chief Operating Officer Caroline Conegliano joins PetMeds as Chief Operating Officer (COO), in a newly created role and expansion of the executive leadership team. Ms. Conegliano brings nearly two decades of experience focused on driving strategic transformation...

Continue reading

KULR Announces Expiration of SEPA Facility and Compliance with NYSE Guidelines on Audit Opinion Disclosure

Written by Customer Service on . Posted in Public Companies.

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today announced that it will not be extending its Standby Equity Purchase Agreement (“SEPA”), with YA II PN, LTD. (“Yorkville”), which terminated on June 1, 2024. Furthermore, the Company confirms that it has retired all outstanding debt owed to Yorkville. This marks a significant milestone for KULR as it executes its strategic initiatives, reduces its cash consumption, and otherwise strengthens its financial condition. Compliance with NYSE Guidelines on Audit Opinion As previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on April 12, 2024, with the Securities...

Continue reading

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

Written by Customer Service on . Posted in Public Companies.

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed Q3W – Tumor CD200 is emerging as a potential biomarker associated with 23ME-00610 monotherapy efficacy SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31-June 4. 23andMe presented two posters on 23ME-00610, one each...

Continue reading

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

Written by Customer Service on . Posted in Public Companies.

Sherry Korczynski joins the leadership team as Senior Vice President, Sales and Marketing Dr. Stephen Wargacki promoted to Chief Science Officer Cassie Jung named Chief Operating Officer WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™ (epinephrine) Sublingual Film, the Company’s epinephrine prodrug product candidate that has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions,...

Continue reading

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

Written by Customer Service on . Posted in Public Companies.

MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), will be presented at the Endocrine Society (ENDO) annual meeting in Boston (June 3) and the Heart in Diabetes (HiD) conference in Philadelphia (June 7). ENDO 2024, Boston Convention & Exhibition CenterLate-Breaking Poster Presentation: Open-label Results From GRACE, A Phase 3 Double-blind, Randomized-withdrawal Study Of The Selective Glucocorticoid...

Continue reading

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on . Posted in Public Companies.

— Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the previously reported 6-month data from IGNYTE trial — — RP2 as monotherapy and in combination with nivolumab in uveal melanoma demonstrates overall response rate of nearly 30 percent; planning for registration-directed trial underway — WOBURN, Mass., June 03, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today presented two oral presentations highlighting promising clinical data from its RP1 and RP2 programs at the 2024 American Society of Clinical Oncology (ASCO)...

Continue reading

DZS Completes NetComm Acquisition

Written by Customer Service on . Posted in Mergers And Acquisitions.

Acquisition creates comprehensive broadband networking, connectivity and cloud software company focused on Americas, Europe, Middle East, Africa and Australia/New Zealand DALLAS, June 03, 2024 (GLOBE NEWSWIRE) — DZS (Nasdaq: DZSI), a developer of Network Edge, Connectivity and Cloud Software solutions enabling broadband everywhere, today announced it has completed its acquisition of NetComm Wireless Pty Ltd. (NetComm). “The NetComm acquisition underscores our commitment to provide communications service providers and enterprise customers with a comprehensive set of connectivity solutions that has now been expanded to include distribution point units (DPUs), WiFi, Fixed Wireless Access (FWA) and industrial Internet of things (IIoT) products,” said Charlie Vogt, President and CEO, DZS. “With NetComm’s market-leading connectivity...

Continue reading

Solstice Announces Acquisition of the Strathy Gold Project in the Abitibi Subprovince, Northeast Ontario

Written by Customer Service on . Posted in Mergers And Acquisitions.

Covers 41 km² of permissive structures including documented high-grade gold VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) — Solstice Gold Corp. (TSXV: SGC) (“Solstice”, “we”, “our” or the “Company”) is pleased to announce the acquisition of a strategic land position centred in Strathy Township in the Temagami Greenstone Belt, Northeastern Ontario. The Strathy Gold Project (“the Project”, or ”SGP”) consists of 45 claims (~41 km2) located in the southeastern part of the prolific Abitibi Subprovince (Figure 1). David Adamson, Solstice’s Chairman stated, “SGP is an extensive land package containing documented, widespread high-grade gold mineralization in this part of the southern Abitibi Subprovince. Despite this demonstrated prospectivity, our core claim holdings have not been systemically explored in the past. This...

Continue reading

Fortrea to Present at the Jefferies Global Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:00 am ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after the conclusion of the event. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.